Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
High-rolling investors have positioned themselves bearish on Eli Lilly (NYSE:LLY), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in LLY often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 39 options trades for Eli Lilly. This is not a typical pattern.
The sentiment among these major traders is split, with 38% bullish and 53% bearish. Among all the options we identified, there was one put, amounting to $42,000, and 38 calls, totaling $5,455,963.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $690.0 to $940.0 for Eli Lilly over the last 3 months.
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 480.38 with a total volume of 1,812.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $690.0 to $940.0 over the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | CALL | SWEEP | BULLISH | 11/15/24 | $236.95 | $234.3 | $237.0 | $700.00 | $2.3M | 756 | 100 |
LLY | CALL | SWEEP | BULLISH | 09/20/24 | $135.8 | $134.05 | $135.8 | $800.00 | $611.9K | 1.3K | 45 |
LLY | CALL | SWEEP | BEARISH | 12/19/25 | $183.55 | $176.1 | $176.3 | $900.00 | $125.0K | 498 | 91 |
LLY | CALL | SWEEP | BEARISH | 12/19/25 | $181.75 | $173.0 | $174.05 | $900.00 | $123.3K | 498 | 1 |
LLY | CALL | SWEEP | BEARISH | 12/19/25 | $179.7 | $173.05 | $174.05 | $900.00 | $123.0K | 498 | 31 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In the last month, 5 experts released ratings on this stock with an average target price of $1017.0.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from Benzinga Pro.
Posted In: LLY